Ulcerative Colitis in Adulthood and in Older Patients: Same Disease, Same Outcome, Same Risks?

por Fries, Walter, Demarzo, Maria Giulia, Navarra, Giuseppe, Viola, Anna
Publicado 2022

Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art

por Savarino, Vincenzo, Marabotto, Elisa, Zentilin, Patrizia, Demarzo, Maria Giulia, de Bortoli, Nicola, Savarino, Edoardo
Publicado 2021

Low Adherence is Associated with Chronic Active Disease in Ulcerative Colitis: A Retrospective Study from a Single Referral Center

por Viola, Anna, Demarzo, Maria Giulia, Abbruzzese, Alfredo, Muscianisi, Marco, Chiappetta, Michele Francesco, Costantino, Giuseppe, Ksissa, Omar, Alibrandi, Angela, Fries, Walter
Publicado 2023

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator

por Cingolani, Linda, Barberio, Brigida, Zingone, Fabiana, Ferronato, Antonio, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Melatti, Piera, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, D’Incà, Renata, Savarino, Edoardo Vincenzo
Publicado 2021

A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study

por Barberio, Brigida, Cingolani, Linda, Canova, Cristina, Barbieri, Giulia, Sablich, Renato, Urbano, Maria Teresa, Bertani, Lorenzo, Costa, Francesco, Bodini, Giorgia, Demarzo, Maria Giulia, Ferronato, Antonio, Buda, Andrea, Melatti, Piera, Massimi, Davide, Savarino, Edoardo Vincenzo, Zingone, Fabiana
Publicado 2021